TRPV1 receptors in the central nervous system: Potential for previously unforseen therapeutic applications

Current Pharmaceutical Design

Volumn 14, Issue 1, 2008, Pages 42-54

  Starowicz, Katarzyna ^a   Cristino, Luigia ^b   Di Marzo, Vincenzo ^a  

^a Institute of Biomolecular Chemistry   (Italy)

^b CNR   (Italy)

Author keywords

Anaridamide; Brain; Capsaicin; Central nervous system; Endovanilloid; TRPV1; Vanilloid

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 [3 (TRIFLUOROMETHYL)PYRIDIN 2 YL] N [4 (TRIFLUOROMETHYLSULFONYL)PHENYL] 1,2,3,6 TETRAHYDROPYRIDINE 4 CARBOXAMIDE; 1 ISOQUINOLIN 5 YL 3 (4 TRIFLUOROMETHYLBENZYL)UREA; 4 (3 TRIFLUOROMETHYLPYRIDIN 2 YL)PIPERAZINE 1 CARBOXYLIC ACID(5 TRIFLUOROMETHYLPYRIDIN 2 YL)AMIDE; 4 AMINOBUTYRIC ACID; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 5' IODORESINIFERATOXIN; 6' IODONORDIHYDROCAPSAICIN; A 425619; A 784168; A 795614; ARACHIDONATE 12 LIPOXYGENASE; ARVANIL; CANNABINOID 1 RECEPTOR; CAPSAICIN; CAPSAZEPINE; CATECHOL METHYLTRANSFERASE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DOPAMINE; FATTY ACID AMIDASE INHIBITOR; GLUTAMIC ACID; GRC 6127; ION TRANSPORT AFFECTING AGENT; JNJ 17203212; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N (4 TERT BUTYLPHENYL) 4 (3 CHLOROPYRIDIN 2 YL)TETRAHYDROPYRAZINE 1(2H)CARBOXAMIDE; N 1H INDAZOL 4 YL N' [(1) 5 PIPERIDIN 1 YL 2,3 DIHYDRO 1H INDEN 1 YL]UREA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 BLOCKING AGENT; VANILLOID RECEPTOR 1 STIMULATING AGENT;

ALLODYNIA; ANALGESIC ACTIVITY; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BONE PAIN; BRADYCARDIA; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; HYPERALGESIA; HYPOTENSION; IRRITABLE COLON; LOCOMOTION; MOOD DISORDER; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; THERMOREGULATION; TRANQUILIZING ACTIVITY; VOMITING;

ANIMALS; BODY TEMPERATURE; BRAIN; CARDIOVASCULAR PHYSIOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; MOOD DISORDERS; MOVEMENT DISORDERS; PAIN; RESPIRATORY PHYSIOLOGY; TRPV CATION CHANNELS; VOMITING;

EID: 39449097036     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783330790     Document Type: Review

References (141)

1. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24.
2. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, et al. The cloned capsaicin receptor integrates multiple pain producing stimuli. Neuron 1998; 21: 531-43.
3. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, Travers JB. Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J Pharmacol Exp Ther 2003; 304: 217-22
4. Birder LA, Kanai AJ, de Groat WC, Kiss S, Nealen ML, Burke NE, et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA 2001; 98: 13396-401
5. Reilly CA, Taylor JL, Lanza DL, Carr BA, Crouch DJ, Yost GS. Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors. Toxicol Sci 2003; 73: 170-81.
6. Heiner I, Eisfeld J, Halaszovich CR, Wehage E, Jüngling E, Zitt C, et al. Expression profile of the transient receptor potential (TRP) family in neutrophil granulocytes: Evidence for currents through long TRP channel 2 induced by ADP-ribose and NAD. Biochem J 2003; 371: 1045-1053.
7. Akiba Y, Kato S, Katsube K, Nakamura M, Takeuchi K, Ishii H, et al. Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet beta cells modulates insulin secretion in rats. Biochem Biophys Res Commun 2004; 321: 219-25.
8. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al. Human brain endothelium: Coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 2004; 132: 87-92.
9. Saunders CI, Kunde DA, Crawford A, Geraghty DP. Expression of transient receptor potential vanilloid 1 (TRPV1) and 2 (TRPV2) in human peripheral blood. Mol Immunol 2007; 44: 1429-1435.
10. Chen CW, Lee ST, Wu WT, Fu WM, Ho FM, Lin WW. Signal transduction for inhibition of inducible nitric oxide synthase and cyclooxygenase-2 induction by capsaicin and related analogs in macrophages. Br J Pharmacol 2003; 140: 1077-1087.
11. Szallasi A, Blumberg PM. Resiniferatoxin and analogs provide novel insights into the pharmacology of vanilloid (capsaicin) receptors. Life Sci 1990a; 47: 1399-1408.
12. Szallasi A, Blumberg PM. Specific binding of resiniferatoxin, an ultrapotent capsaicin analog, by dorsal root ganglion membranes. Brain Res 1990b; 524: 106-111.
13. Szallasi A, Joo F, Blumberg PM. Duration of desensitization and ultrastructural changes in dorsal root ganglia in rats treated with risiniferatoxin, an ultrapotent capsaicin analog. Brain Res 1989; 503: 68-72.
14. Szallasi A, Szolcsanyi J, Szallasi Z, Blumberg PM. Inhibition of [3H]resiniferatoxin binding to rat dorsal root ganglion membranes as a novel approach in evaluating compounds with capsaicin-like activity. Naunyn Schmiedebergs. Arch Pharmacol 1991; 344: 551-6.
15. Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S, et al. Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 2004; 279: 20283-20295.
16. Walpole CS, Wrigglesworth R, Bevan S, Campbell EA, Dray A, James IF, et al. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region". J Med Chem 1993; 36: 2362-72.
17. Walpole CS, Wrigglesworth R, Bevan S, Campbell EA, Dray A, James IF, et al. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region". J Med Chem 1993; 36: 2373-80.
18. Walpole CS, Wrigglesworth R, Bevan S, Campbell EA, Dray A, James IF, et al. Analogues of capsaicin with agonist activity as novel analgesic agents, structure-activity studies. 3. The hydrophobic side-chain "C-region". J Med Chem 1993; 36: 2381-9.
19. Appendino G, Minassi A, Schiano Moriello A, De Petrocellis L, Di Marzo V. N-Acylvanillamides: Development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor. J Med Chem 2002; 45: 3739-45
20. Brand L, Berman E, Schwen R, Loomans M, Janusz J, Bohne R, et al. NE-19550: A novel, orally active anti-inflammatory analgesic. Drugs Exp Clin Res. 1987; 13: 259-65.
21. Di Marzo V, Bisogno T, Melck D, Ross R, Brockie H, Stevenson L, et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett 1998; 436: 449-54.
22. Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M, et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 1999; 262: 275-84.
23. Di Marzo V, Breivogel C, Bisogno T, Melck D, Patrick G, Tan Q, et al. Neurobehavioral activity in mice of N-vanillyl-arachidonylamide. Eur J Pharmacol 2000; 406: 363-74.
24. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, et al. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun. 2001a; 281: 444-51.
25. Di Marzo V, Griffin G, De Petrocellis L, Birandi I, Bisogno T, Williams W, et al. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J Pharmacol Exp Ther 2002 Mar; 300: 984-91.
26. Appendino G, De Petrocellis L, Trevisani M, Minassi A, Daddario, N, Schiano Moriello A, et al. Development of the fist ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential. J Pharmacol Exp Ther 2005; 312: 56-70.
27. Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, et al. N-acyl-dopamines: Novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000; 351: 817-24.
28. Huang SM, Bisogno, T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous, capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002; 99: 8400-8405.
29. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2600; 288: 306-13.
30. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405: 183-187.
31. Kamei J, Zushida K, Morita K, Sasaki M, Tanaka S. Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice. Eur J Pharmacol 2001; 422: 83-6.
32. Szallasi A, Cortright DN, Blum CA, Erd SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007; 6: 357-72.
33. Docherty RJ, Yeats JC, Piper AS: Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture. Br J Pharmacol 1997; 121: 1461-7.
34. Teng HP, Huang CJ, Yeh JH, Hsu SS, Lo YK, Cheng JS, et al. Capsazepine elevates intracellular Ca2+ in human osteosarcoma cells, questioning its selecvity as a vanilloid receptor antagonist. Life Sci 2004; 15: 2515-26.
35. Dickenson AH, Dray A. Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception. Br J Pharmacol 1991; 104: 1045-9.
36. Dickenson AH. Clipsaicin: Gaps in our knowledge staff to be filled. Trends Neurosci 1991; 14: 265-6.
37. Szallasi A, Appendino G. Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we puting the cart before the horse? J Med Chem 2004; 47: 2717-23.
38. Valenzano KJ, Sun Q. Current perspectives on the therapeutic utility of VRI antagonists. Curr Med Chem 2004; 11: 3185-202.
39. Wahl P, Foged C, Tullin S, Thomsen C. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol 2001; 59: 9-15.
40. Rigoni M, Trevisani M, Gazzieri D, Nadaletto R, Tognetto M, Creminon C, et al. Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodoresiniferatoxin. Br J Pharmacol 2003; 138: 977-85.
41. Appendino G, Harrison S, De Petrocellis L, Daddario N, Bianchi F, Schiano Moriello A, et al. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br J Pharmacol. 2003; 139: 1417-24.
42. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, et al. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 2004; 46: 133-49.
43. Swanson DM, Dubin AE, Shah C, Nasser N, Chang L, Dax SL, et al. Identification and biological evaluation of 4-(3-trifluoromethyl-pyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem 2005; 48: 1857-72.
44. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, et al. AMG 9810 ((E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4) dioxin-6-yl)acrylamide), a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2005; 313: 474-84.
45. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, et al. Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006; 16: 3287-91.
46. El Kouhen R, Surowy CS, Bianchi BR, Neelands TR, McDonald HA, Niforatos W, et al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Their 2005; 314: 400-9.
47. Honore P, Wisner CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, et al. A-425619 (1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea), a novel transient receptor potential type V1 receptor antagonist, relieves pathophygiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005; 314: 410-21.
48. Pomonis JD, Harrison JE Mark L, Bristol DR, Valenzano KJ, Walker K. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl) tetrahydroprazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003; 306: 387-93.
49. Szallasi A, Cruz F, Geppetti P. TRPV1: A therapeutic target for novel analgesic drugs? Trends Mol Med 2006; 12: 545-54.
50. Dax S, Dubin A, Jetter M, Nasser N, Shah C, Swanson D, et al. Vanilloid receptor antagonists: Structure activity relationships via parallel and targeted synthesis. Int Symp Med Chem 2002; 27: 93.
51. Sterner O, Szllasi A. Novel natural vanilloid receptor agonists: New therapeutic targets for drug development. Trends Pharmacol Sci 1999; 20: 459-65.
52. Garcia-Martinaz C, Humet M, Planells-Cases R, Gomis A, Caprini M, Viana F, et al. Attenuation of thermal nociception and hyperalgesia by VR1 blockers. Proc Natl Acad Sci USA 2002; 99: 2374-9.
53. Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB. et al. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 2001; 420: 123-31.
54. Hajos M, Svensson K, Nissbrandt H, Obal F Jr, Carlsson A. Effects of capsaicin on central monoaminergic mechanisms in the rat. J Neural Transm 1986; 66: 221-42.
55. Hu DE, Easton AS, Fraser PA. TRPV1 activation results in disruption of the blood-brain barrier in the rat. Br J Pharmacol 2005; 146: 576-84
56. Kang YS, Kim JM.Permeability of a capsaicin derivative, [14C] DA-5018, to blood-brain barrier corrected with HPLC method. Arch Pharm Res 1999; 22: 165-72.
57. Cui M, Mnore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006; 26: 9385-93.
58. Gayva NR, Bannon AW, Surapaneni S, Hovland DN Jr, Lehto SG, Gore A, et al. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 2007; 27: 3366-74.
59. Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1, like immunoreactivity, in in the central nervous system of the rat and human. Proc Natl Acad Sci USA 2000; 97: 3655-60.
60. Szabo T, Biro T, Gonzalez AF, Palkovits M, Blumberg PM: Pharmacological characterization of vanilloid receptor located in the brain. Brain Res Mol Brain Res 2002; 98: 51-57.
61. Sanchez JF, Krause JE, Cortright DN: The distribution and regulation of vanilloid receptor VR1 and VR1 5′ splice variant RNA expression in rat. Neuroscience 2001; 107: 373-381.
62. Roberts JC, Davis JB, Benham CD. (3H)Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res 2004; 995: 176-183.
63. Liapi A, Wood JN. Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur J Neurosci 2005; 22: 825-834.
64. Toth A, Boczan J, Kedei N, Lizanecz E, Bagi Z, Papp Z, et al. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 2005; 135: 162-168.
65. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006; 139: 1405-15.
66. Szallasi A, Di Marzo V. New perspectives on enigmatic vanilloid receptors. Trends Neurosci 2000; 23: 491-7.
67. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003; 140: 790-801.
68. van der Stelt M, Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004; 271: 1827-34.
69. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007; 114: 13-33.
70. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 490: 452-7.
71. Park YH, Lee SS. Identification and characterization of capsaicin-hydrolyzing enzymes purified from rat liver microsomes. Biochem Mol Biol Int 1994; 34: 351-60.
72. Koulchitsky SV, Azev OA, Gourine AV, Kulchitsky VA. Capsaicin-sensitive area in the ventral surface of the rat medulla. Neurosci Lett; 182: 129-32.
73. Rabe LS, Buck SH, Moreno L, Burks TF, Dafny N. Neurophysiological and thermoregulatory effects of capsaicin. Brain Res Bull 1986; 5: 755-8
74. Jancsó-Gábor A, Szolcsányi J, Jancsó. N.Stimulation and desensitization of the hypothalamic heat-sensitive structures by capsaicin in rats. J Physiol 1970; 208; 449-59.
75. Sasamura T, Kuraishi Y. Peripheral and central action of capsaicin and VR1 receptor. Jpn J Pharmacol 1999; 80: 275-80.
76. Karlsson U, Sundgren-Andersson AK, Johansson S, Krupp JJ. Capsaicin augments synaptic transmission in the rat medial preoptic nucleus. Brain Res 2005; 1043: 1-11.
77. Hajós M, Engberg G, Nissbrandt H, Magnusson T, Carlsson A. Capsaicin-sensitive vasodilatatory mechanisms in the rat substantia nigra and striatum. J Neural Transm 1988: 74: 129-39.
78. Osaka T, Lee TH, Kobayashi A, Inoue S, Kimura S. Thermogenesis mediated by a capsafcin-sensitive area in the ventrolateral medulla. Neuroreport 2000; 11: 2425-8.
79. Hori T, Shibata M, Kiyohara T, Nakashima T, Asami A. Responses of anterior hypothalamic-preoptic thermosensitive neurons to locally applied capsaicin. Neuropharmacology 1988; 27: 135-42.
80. Gavva NR, Bannon AW, Hovland Jr DN, Lehto SG, Klionsky L, Surapaneni S, et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 2007; 323: 128-37.
81. Lukovic L, de Jong W, de Wied D. Cardiovascular effects of substance P and capsaicin microinjected into the nucleus tractus solitarii of the rat. Brain Res 1987; 422: 312-8.
82. Mazzone SB, Geraghty DP. Altered respiratory response to substance P and reduced NK1 receptor binding in the nucleus of the solitary tract of aged rats. Brain Res 1999; 826: 139-42.
83. Geraghty DP, Mazzone SB. Respiratory actions of vanilloid receptor agonists in the nucleus of the solitary tract: Comparison of resiniferatoxin with non-pungent agents and anandamide. Br J Pharmacol 2002; 137: 919-27.
84. Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 2007; 25: 2773-82.
85. Andrews PL, Okada F, Woods AJ, Hagiwara H, Kakaimoto, S, Toyoda M, et al. The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol. 2000; 130: 1247-54.
86. Rudd JA, Wai MK. Genital grooming and emesis induced by vanilloids in Suncus murinus, the house musk shrew. Eur J Pharmacol 2001; 422: 185-95.
87. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001; 121: 767-74.
88. Darmani NA. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/ inverse agonist SR 141716A. Neuropsychopharmacology 2001; 24: 198-203.
89. Maione S, Starowicz K, Palazzo E, Rossi F, Di Marzo V. The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain. Drug Dev Res 2006; 67: 339-354.
90. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 2006; 316: 969-82
91. Palazzo E, de Novellis V, Marabese I, Cuomo D, Rossi F, Berrino L, et al. Interaction between vanilloid and glutamate receptors in the central modulation of nociception. Eur J Pharmacol 2002; 439: 69-75
92. McGaraughty S, Chu KL, Bitner RS, Martino B, El Kouhen R, Han P, et al. Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. J Neurophysiol 2003; 90: 2702-10.
93. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007; 150: 766-81.
94. Starowicz K, Maione S, Cristino S, Palazzo F, Marabese I, Rossi F, et al. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci, In press.
95. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474.
96. Steenland HW, Ko SW, Wu LJ, Zhuo M. Hot receptors in the brain. Mol Pain 2006; 2: 34.
97. Calejesan AA, Kim SJ, Zhuo M. Descending facilitatory modulation of a behavioral nociceptive response by stimulation in the adult rat anterior cingulate cortex. Eur J Pain 2000; 4: 83-9.
98. Tang J, Ko S, Ding HK, Qiu CS, Calejesan AA, Zhuo M. Pavlovian fear memory induced by activation in the anterior cingulate cortex. Mol Pain 2005; 1: 6.
99. Xing J, Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 2007; 97: 503-11.
100. 1 Receptor activation induces glutamate release and postsynaptic firing in the paraventricular nucleus. J Neurophysiol 2004; 92: 1807-1816.
101. Jin YH, Bailey TW, Li BY, Schild JH, Andresen MC. Purinergic and vanilloid receptor activation releases glutamate from separate cranial afferent terminals in nucleus tractus solitarius. J Neurosci 2004; 24: 4709-17.
102. Marinelli S, Vaughan CW, Christie MJ, Connor M. Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol 2002; 543: 531-40.
103. Marinelli S, Di Marzo V, Berretta N, Matias I, Maccarrone M, Bernardi G, et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci 2003; 23: 3136-44.
104. Derbenev AV, Monroe MJ, Glatzer NR, Smith BN. Vanilloid-mediated heterosynaptic facilitation of inhibitory synaptic input to neurons of the rat dorsal motor nucleus of the vagus. J Neurosci 2006; 26: 9666-72.
105. Sikand P, Premkumar LS. Potentiation of Glutamatergic Synaptic Transmission by Protein Kinase C Mediated Sensitization of TRPV1 at the First Sensory Synapse. J Physiol 2007; 581: 631-47.
106. Hajós M, Jancsó G, Engberg G. Capsaicin-induced excitation of locus coeruleus neurons Acta Physiol Scand 1987; 129: 415-20.
107. Andoh R, Onodera K, Shima K, Kisara K. Effects of capsaicin on spontaneous unit discharges in medial thalamic single neurons of cats. Nippon Yakurigaku Zasshi 1977; 73: 955-9.
108. Andoh R, Shima K, Miyagawa T, Sakurada S, Kisara K, Ohsawa K, et al. Excitatory effects of dihydrocapsaicin on nociceptive neurons in the medial thalamus. Jpn J Pharmacol 1980; 30: 599-605.
109. Andoh R, Sakurada S, Sato T, Takahashi N, Kisara K. Potentiating effects of prostaglandin E2 on bradykinin and capsaicin responses in medial thalamic nociceptive neurons. Jpn J Pharmacol 1982; 32: 81-9
110. Dawbarn D, Harmar AJ, Pycock CJ. Intranigral injection of capsaicin enhances motor activity and depletes nigral 5-hydroxytryptamine but not substance P. Neuropsychopharmacology 2005; 30: 864-70.
111. Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Perez-Rosado A, Manzanares J, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntingtons disease. Synapse 2002; 44: 23-35.
112. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J. Compounds acting at the endocannabinoid and/ or endovanilloid systems reduce hyperkinesia in a rat model of Huntingtons disease. J Neurochem 2003; 84: 1097-109.
113. Kim SR, Lee DY, Chung ES, Oh UT, Kim SU, Jin BK. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo, and in vitro. J Neurosci 2005; 25: 662-71
114. Marinelli S, Di Marzo V, Florenzano F, Fezza F, Viscomi MT, van der Stelt M, et al. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 2007; 32: 298-308.
115. de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryo G, et al. In vivo pharmacological actions of two novel inhibitprs of anandamide cellular uptake, Eur J Pharmacol 2004; 484: 249-57.
116. Cabranes A, Venderova K, de Lago E, Fezza F, Sanchez A, Mestre L, et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005; 20: 207-17.
117. Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, et al. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-relaield hyperactivity: Therapeutic implications. Biol Psychiatry 2006; 59: 508-15.
118. Lee J, Di Marzo V. Brotchie JM. A role for vanilloid receptor I (TRPV1) and endocannabinnoid signalling, in the regulationr of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology 2006; 51: 557-65.
119. Morgese MG, Cassano T, Cuomo V, Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinsons disease: Role of CB(1) and TRPV1 receptors. Exp Neurol 2007; 208: 110-10.
120. Marsch R, Foeller E, Rammes G, Bunck M, Kösl M, Holsboer F, et al. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type receptor-deficient mice. J Neurosci 2007; 27: 832-9.
121. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992; 89: 3825-9
122. van der Stelt M, Trevisani M, Vellani V, De Petrocellis L, Schiano Moriello A, Campi B, et al. Anandamide acts as an intracellular messenger amplifying Ca2+influx via TRPV1 channels. EMBO J 2005; 24: 3026-37.
123. Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs 2006; 66: 2109-19.
124. Kasckow JW, Mulchahey JJ, Geracioti TD Jr. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 291-5.
125. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
126. Ortar, Cascio M.G, De Petrocellis L, Morera E, Rossi F, Schiano Moriello A, et al. New N-arachidonoylserotonin analogues with potential 'dual' mechanism of action against pain. J Med Chem 2007; In press
127. Doyle MW, Bailey TW, Jin YH, Andresen MC. Vanilloid receptors presynaptically modulate cranial visceral afferent synaptic transmission in nucleus tractus solitarius. J Neurosci 2002; 22: 8222-9.
128. Bailey TW, Jin YH, Doyle MW, Andresen MC. Vanilloid-sensitive afferents activate neurons with prominent A-type potassium currents in nucleus tractus solitatius. J Neurosci 2002; 22: 8230-7.
129. Al-Hayani A, Wease KN, Ross RA, Pertwee RG, Davies SN. The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology 2001; 41: 1000-5.
130. Kof̈alvi A, Oliveira CR, Cunha RA. Lack of evidence for functional TRPV1 vanilloid receptors in rat hippocampal nerve terminals. Neurosci Lett 2006; 403: 151-6.
131. Benninger F, Freund TF, Hájos N. Control of excitatory synaptic transmission by capsaicin is unaltered in TRPV(1) vanilloid receptor knockout mice. Neurochem Int. 2007; [Epub ahead of print].
132. Movahed P, Jonsson BA, Birnir B, Wingstrand JA, Jorgensen TD, Ermund A, et al. Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem 2005; 280: 38496-504
133. Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 2003; 278: 13633-9.
134. De Petrocellis L, Chu CJ, Moriello AS, Kellner JC, Walker JM, Di Marzo V. Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPVI) channels. Br J Pharmacol 2004; 143: 251-6.
135. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000; 97: 6155-60.
136. Cristino L, Starowicz K, De Petrocellis L, Morishita J, Ueda N, Guglielmotti V, et al. Immunohistochemical localization of anabolic and catabolic enzymes 'for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience, in press.
137. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 2001; 276: 12856-12863.
138. Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S, et al. Molecular determinants of vanilloid sensitivity in TRPVI. J Biol Chem 2004, 279: 20283-95.
139. Evangelista S. Role of sensory neurons in restitution and healing of gastric ulcers. Curr Pharm Des 2006; 12(23): 2977-84.
140. Maccarrone M. Fatty acid amide hydrolase: A, potential target for next generation therapeutics. Curr Pharm Des 2006; 12(6): 759-72.
141. Staud R. Are tender point injections beneficial: The role of tonic nociception in fibromyalgia. Curr Pharm Des 2006; 12(1): 23-7.